Qidii, Inc. reports successful human proof-of-concept for its Qi601 technology, confirming the device's efficacy in capturing microplastics in a peer-reviewed study.
First-in-human study demonstrates Qi601 can physically capture microplastics, a positive clinical milestone for Qidii.
Qidii, Inc. shares gained momentum following the release of peer-reviewed research confirming the first human proof-of-concept for its Qi601 technology. The study demonstrates the device's ability to physically capture microplastics, marking a significant clinical milestone for the company's environmental health platform.
The study provides the first human proof-of-concept evidence that the Qi601 technology can effectively and physically capture microplastics from the environment.